Hosted by Jesús E. Moreno, Business Development Director at bioaccess®, the Global Trial Accelerators™ podcast is the only show built for healthcare startup founders, investors, and innovators navigating first-in-human (FIH) clinical trials. The show is produced by bioaccess® and was founded by Co-Founder & CEO Julio G. Martinez-Clark.
90% of healthcare startups fail — not because their technology doesn’t work, but because they run out of capital before generating the clinical data investors need to see. bioaccess® is the world’s only CRO purpose-built exclusively for FIH trials — serving MedTech, Biopharma, and Radiopharma startups. Each episode delivers actionable strategies from clinical trial pioneers, regulatory strategists, and startup founders who have accelerated their timelines, improved cost-efficiency, and generated regulator-ready clinical data by leveraging Latin America’s 19-country clinical research network.
What You’ll Learn:
• How emerging-market regulatory pathways can shorten ethics-approval timelines compared with the US/EU
• Regulatory pathways across Latin America (Colombia, Mexico, Brazil, Chile, Argentina, Panama, Ecuador, El Salvador, Dominican Republic, Paraguay, and more)
• How to generate FIH clinical data that supports funding rounds, FDA submissions, and strategic acquisitions
• The Innovation Runway: from prototype to clinical milestones before capital runs out
• How emerging markets can improve per-patient and overall trial cost-efficiency
• Market access strategies for registering and commercializing your device across Latin America
• Case studies from dozens of companies — seed-stage startups to Fortune 500 MedTech
Who Should Listen:
• MedTech, Biopharma, and Radiopharma startup founders & CEOs
• Clinical development and regulatory affairs leaders
• Healthcare investors and venture capital partners
• Innovation officers at Fortune 500 medical device companies
• Anyone navigating the path from concept to first-in-human clinical evidence
Subscribe now and join the founders who are accelerating their path to clinical proof — and to exit.
